CBP501

CBP501 is a peptide with G2 checkpoint-abrogating activity. G2 checkpoint inhibitor CBP501 inhibits multiple serine/threonine kinases, including MAPKAP-K2, C-Tak1, and CHK1, that phosphorylate serine 216 of the dual-specific phosphatase Cdc25C (cell division checkpoint 25 C) ; disruption of Cdc25C activity results in the inhibition of Cdc25C dephosphorylation of the mitotic cyclin-dependent kinase complex Cdc2/cyclin B, preventing entry into the mitotic phase of the cell cycle.

C([C@H](C(N[C@@H](C(N[C@H](CC1=C(F)C(F)=C(F)C(F)=C1F)C(N[C@H](CC2CCCCC2)C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@H](CCCNC(=N)N)C(O)=O)=O)CCCNC(=N)N)=O)CCC(N)=O)=O)CCCNC(=N)N)=O)CCCNC(=N)N)=O)CCCNC(=N)N)=O)=O)=O)CO)=O)NC([C@H](NC([C@@H](CC3=CC=C(C(=O)C4=CC=CC=C4)C=C3)N)=O)CO)=O)C=5C=6C(NC5)=CC=CC6